Drug profile

The FDA adverse-event record for Unknown Product

24 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unknown Product. See the species affected, top reactions, and outcomes below.

24
adverse-event reports
20.8%
death-coded share
Dog
most-reported species
4
Death by euthanasia - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
24
Total Reports
5
Deaths Reported
20.8%
Death Rate

Active Ingredients

Unknown Product

Administration Routes

UnknownTopicalSubcutaneousAuricular (Otic)Oral

Species Affected

Dog 18
Cat 5
Cattle 1

Most Affected Breeds

Retriever - Labrador 4
Dog (unknown) 3
Newfoundland 3
Shepherd Dog - German 2
Cat (other) 2
Domestic Shorthair 1
Crossbred Canine/dog 1
Cattle (other) 1
Cat (unknown) 1
Terrier - Yorkshire 1

Most Reported Reactions

Death by euthanasia 4
Lethargy (see also Central nervous system depression in Neurological) 4
Other abnormal test result NOS 4
Lack of efficacy (bacteria) - Borrelia 3
Intentional misuse 3
Ataxia 3
Walking difficulty 3
Tachycardia 3
Difficulty to rise 3
Eye disorder NOS (for Photophobia see neurological) 3
Paralysis 3
Partial lack of efficacy 3

Outcome Breakdown

Ongoing
8 (33.3%)
Outcome Unknown
7 (29.2%)
Euthanized
4 (16.7%)
Recovered with Sequela
2 (8.3%)
Recovered/Normal
2 (8.3%)
Died
1 (4.2%)

Unknown Product Adverse Event Insights

24 reports name Unknown Product; 5 recorded a death outcome (20.8% of reported events, not a population-level mortality rate). Active ingredient: Unknown Product. Administration routes: Unknown, Topical, Subcutaneous, Auricular (Otic).

By species: Dog (18 reports), Cat (5 reports), Cattle (1 reports). By breed: Retriever - Labrador (4), Dog (unknown) (3), Newfoundland (3).

Leading clinical signs: Death by euthanasia (4), Lethargy (see also Central nervous system depression in Neurological) (4), Other abnormal test result NOS (4), Lack of efficacy (bacteria) - Borrelia (3). Outcome, 24 coded reports: Ongoing leads at 33.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.